Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an extremely lethal disease and accounts for more than 90% of pancreas tumors. The high lethality is due, in part, to the tumor intrinsic or acquired chemotherapeutic resistance and to the high metastatic potential of this type of cancer, with metastasis being an early event in the PDAC evolution and present in 50% of diagnosed patients. The tumo…